Fructosamine Test Industry

The global fructosamine test indutry was valued at around in 2023 and is poised to exhibit a CAGR of during the forecast period. Accordingly, total market valuation is expected to increase from in 2024 to by 2034.

Several factors are anticipated to drive the growth of the fructosamine test industry over the assessment period. These include increasing incidence of diabetes and obesity, growing awareness about fructosamine testing, and rising need for efficient blood glucose monitoring diagnostic tests.

Fructosamine testing has become a widely used method for measuring blood glucose. It does not require fasting and can be helpful when an HbA1c test is unreliable.

There has been a sharp rise in cases of diabetes during the last few years. For instance, according to the International Diabetes Federation, around 537 million adults were living with diabetes in 2021. This, in turn, is expected to uplift demand for fructose tests.

Fructosamine testing is an important method that helps medical professionals monitor glycemic management in diabetics. The growing demand for these monitoring technologies highlights the need to address the expanding diabetes epidemic. It also shows the critical role innovative approaches, such as fructosamine testing, play in treating and reducing the effects of this chronic condition.

Another notable trend is the growing focus on fructosamine point-of-care diagnostics, which provide quick and easy glycemic control monitoring at the patient’s location. This change speeds up the evaluation of fast-acting blood glucose levels, allowing for rapid medical choices.

Point-of-care testing minimizes the need for a large laboratory infrastructure by streamlining the diagnostic procedure and providing instant results. This trend supports proactive diabetes management by improving patient accessibility to timely healthcare information, which is the primary goal.

Point-of-care fructosamine tests are a major improvement in decentralized healthcare due to their accessibility and speed. They significantly promote quicker interventions and improve overall patient outcomes.

says an analyst of Future Market Insights (FMI).

The primary strategies employed by the industry’s leading manufacturers include new product launches, distribution agreements, partnerships, acquisitions, and collaborations. Several companies are also launching awareness programs and campaigns to expand their customer base.

Beckman Coulter, Inc.; Randox Laboratories Ltd.; Fortress Diagnostics; KAMIYA BIOMEDICAL COMPANY; Abbexa; Weldon Biotech, Inc.; Eurolyser Diagnostica GmbH; F. Hoffmann-La Roche Ltd; Asahi Kasei Pharma Corporation (EKF DIAGNOSTICS); LifeSpan BioSciences, Inc; Zhejiang Kangte Biotechnology Co., Ltd.; Diazyme; Abcam plc.; Weldon Biotech, Inc.; Bio Vision; Mybiosource

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: [email protected]
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube